Type 2 diabetes mellitus in 2012: Optimal management of T2DM remains elusive - PubMed (original) (raw)

Review

Type 2 diabetes mellitus in 2012: Optimal management of T2DM remains elusive

Rury R Holman. Nat Rev Endocrinol. 2013 Feb.

Abstract

Worldwide, >366 million people with type 2 diabetes mellitus remain at excess risk of cardiovascular disease and face a lifetime of treatment escalation for this progressive disorder. Studies in 2012 have re-affirmed the safety of early insulin treatment, metformin use in renal impairment, and shown β-cell function preservation over several years.

PubMed Disclaimer

Similar articles

• Metformin: diamonds are forever.
  Papanas N, Maltezos E, Mikhailidis DP. Papanas N, et al. Expert Opin Pharmacother. 2009 Oct;10(15):2395-7. doi: 10.1517/14656560903176453. Expert Opin Pharmacother. 2009. PMID: 19678795
• Metformin: a multitasking medication.
  Bailey CJ. Bailey CJ. Diab Vasc Dis Res. 2008 Sep;5(3):156. doi: 10.3132/dvdr.2008.026. Diab Vasc Dis Res. 2008. PMID: 18777487 No abstract available.
• Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.
  Guarino E, Nigi L, Patti A, Fondelli C, Dotta F. Guarino E, et al. Expert Opin Pharmacother. 2012 Jun;13(9):1377-84. doi: 10.1517/14656566.2012.667078. Epub 2012 Mar 7. Expert Opin Pharmacother. 2012. PMID: 22397507 Review.
• The diabetologist/cardiologist debate: a meeting of the minds.
  Mohamed F, Aalbers J. Mohamed F, et al. Cardiovasc J Afr. 2012 Mar;23(2):115-7. Cardiovasc J Afr. 2012. PMID: 22447480 No abstract available.
• Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
  Yandrapalli S, Jolly G, Horblitt A, Sanaani A, Aronow WS. Yandrapalli S, et al. Postgrad Med. 2017 Nov;129(8):811-821. doi: 10.1080/00325481.2017.1358064. Epub 2017 Jul 27. Postgrad Med. 2017. PMID: 28749197 Review.

Cited by

• Excessive iron inhibits insulin secretion via perturbing transcriptional regulation of SYT7 by OGG1.
  Zhao X, Ma Y, Shi M, Huang M, Xin J, Ci S, Chen M, Jiang T, Hu Z, He L, Pan F, Guo Z. Zhao X, et al. Cell Mol Life Sci. 2023 May 20;80(6):159. doi: 10.1007/s00018-023-04802-y. Cell Mol Life Sci. 2023. PMID: 37209177 Free PMC article.
• Effective Therapeutic Delivery and Bioavailability Enhancement of Pioglitazone Using Drug in Adhesive Transdermal Patch.
  Nair AB, Gupta S, Al-Dhubiab BE, Jacob S, Shinu P, Shah J, Morsy MA, SreeHarsha N, Attimarad M, Venugopala KN, Akrawi SH. Nair AB, et al. Pharmaceutics. 2019 Jul 23;11(7):359. doi: 10.3390/pharmaceutics11070359. Pharmaceutics. 2019. PMID: 31340601 Free PMC article.
• The PI3K/AKT pathway in obesity and type 2 diabetes.
  Huang X, Liu G, Guo J, Su Z. Huang X, et al. Int J Biol Sci. 2018 Aug 6;14(11):1483-1496. doi: 10.7150/ijbs.27173. eCollection 2018. Int J Biol Sci. 2018. PMID: 30263000 Free PMC article. Review.
• Evaluating the antidiabetic effects of Chinese herbal medicine: Xiao-Ke-An in 3T3-L1 cells and KKAy mice using both conventional and holistic omics approaches.
  Yang Z, Wang L, Zhang F, Li Z. Yang Z, et al. BMC Complement Altern Med. 2015 Aug 13;15:272. doi: 10.1186/s12906-015-0785-2. BMC Complement Altern Med. 2015. PMID: 26268726 Free PMC article.
• Lactobacillus casei reduces susceptibility to type 2 diabetes via microbiota-mediated body chloride ion influx.
  Zhang Y, Guo X, Guo J, He Q, Li H, Song Y, Zhang H. Zhang Y, et al. Sci Rep. 2014 Jul 18;4:5654. doi: 10.1038/srep05654. Sci Rep. 2014. PMID: 25133590 Free PMC article.

References

1. 1. BMJ Open. 2012 Jul 13;2(4): - PubMed
2. 1. Diabetes Care. 1995 Aug;18(8):1113-23 - PubMed
3. 1. Diabetes Care. 2013 Aug;36(8):2254-61 - PubMed
4. 1. N Engl J Med. 2012 Jul 26;367(4):319-28 - PubMed
5. 1. Diabetes Care. 2012 Jul;35(7):1406-12 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group
  • Ovid Technologies, Inc.

• Other Literature Sources

  • scite Smart Citations

• Medical

  • MedlinePlus Health Information